MC
AKBA icon

Maverick Capital’s Akebia Therapeutics AKBA Stock Holding History

Maverick Capital’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-105,816
Closed -$305K – 324
2021
Q3 		$305K Buy
+105,816
New +$302K ﹤0.01% 493
2021
Q2 		– Sell
-140,352
Closed -$475K – 669
2021
Q1 		$475K Buy
+140,352
New +$506K ﹤0.01% 391

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Maverick Capital's AKBA Position: Q4 2021 in Review

Maverick Capital sold out of Akebia Therapeutics (AKBA) in Q4 2021, closing a stake of 105,816 shares — an estimated $305K sold.

Maverick Capital first reported a position in AKBA in Q1 2021 and held it in 2 quarters. The position peaked at $475K in Q1 2021. 133 funds tracked by Wall St. Rank hold AKBA as of Q4 2021.

  • Maverick Capital reported no remaining Akebia Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Maverick Capital sold 105,816 Akebia Therapeutics shares in Q4 2021, an estimated $305K.
  • Maverick Capital first reported a position in Akebia Therapeutics in Q1 2021 and held it in 2 quarters.
  • Maverick Capital's Akebia Therapeutics position peaked at $475K in Q1 2021.
  • 133 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2021.

Based on Maverick Capital's 13F filing for Q4 2021, filed 14 Feb 2022.